Metatop (Lormetazepam)

Lormetazepam, the active ingredient in Metatop, is a benzodiazepine presented as an oral tablet for oral use. It is indicated for the short‑term treatment of insomnia in adult patients. GNH USA supplies Metatop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lormetazepam is a benzodiazepine hypnotic that acts on the central nervous system to facilitate sleep. - Insomnia (sleep onset): helps patients fall asleep more quickly. - Insomnia (sleep maintenance): reduces nighttime awakenings and improves sleep continuity. - Insomnia (short‑term use): provides temporary relief of sleep disturbance for up to four weeks.

Lormetazepam may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness: feeling unusually sleepy during the day. - Dizziness: light‑headed sensation, especially when standing quickly. - Fatigue: reduced energy and motivation. - Memory impairment: difficulty recalling recent events. - Ataxia: uncoordinated movements or gait instability. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, especially with other depressants. - Dependence or withdrawal syndrome: cravings, anxiety or seizures on abrupt cessation. - Paradoxical reactions: agitation, aggression or increased anxiety. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Depression or suicidal ideation: mood changes requiring urgent medical attention. - Hepatic dysfunction: abnormal liver enzymes or jaundice.

Before prescribing Lormetazepam, clinicians should consider several safety factors. - Use in elderly: increased risk of falls and cognitive impairment. - Abrupt discontinuation: may precipitate withdrawal symptoms; tapering is recommended. - Hepatic impairment: reduced metabolism may increase drug exposure. - Concomitant alcohol: additive central nervous system depression. - Pregnancy: limited safety data; avoid unless benefit outweighs risk. - Store at room temperature: keep in the original pack, protect from moisture.

Lormetazepam can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Opioids or other CNS depressants: risk of profound sedation or respiratory depression. - Alcohol: additive sedative effect, increasing impairment. - Ketoconazole or other strong CYP3A4 inhibitors: may raise plasma concentrations.

Moderate Interactions (Monitor Closely): - Erythromycin or other moderate CYP3A4 inhibitors: may modestly increase levels. - Rifampicin or other CYP3A4 inducers: may reduce therapeutic effect. - Selective serotonin reuptake inhibitors (SSRIs): can enhance sedation.